• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·6744.TWO
Share

Feng Chi Biotech Corp. Stocks

NT$ 13.8Last Updated 29.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

NT$ 7.24M

NT$ 13.8
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Feng Chi Biotech Corp., a company based in Taipei, Taiwan, specializes in offering a diverse range of diagnostic and scientific services. Their core activities encompass genetic screening for both pre-implantation and prenatal stages, comprehensive life science support, and early detection screening for newborns. Additionally, they perform microbiological assessments for the food and pharmaceutical sectors, alongside engaging in medical translational research. The company also acts as a supplier for various genetic testing technologies and products specifically tailored for the field of oncology.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair value on

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

30.07.2026 16:50

Shares of the micro-cap biotech company Processa plummeted following the announcement of a merger. What went wrong?

30.07.2026 16:15

Opinion: The AI Boom vs. the Dot-Com Era. What Are Their Main Differences?

30.07.2026 15:50

July Could Be the Worst Month for Chinese Stocks in 10 Years

30.07.2026 15:40

Morning in New York: Focus on Inflation Data, New Reports from Big Tech, and Geopolitics

30.07.2026 15:00

IPO Reformation: The Brand That Dressed Taylor Swift and Jennifer Aniston Goes Public

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026